VEGFA and hereditary clear cell renal cell carcinoma: Nearly all patients who initially respond to these treatments acquire resistance, and there is an unmet medical need for new agents targeting angiogenesis and tumor growth in patients with renal cell carcinoma that was previously treated with at least two systemic therapies including VEGF targeted therapies and mTOR inhibitors [2].